Showing results (651-660 of 2,811) with videos related to
Sort By:
Pageof 282
Expert Opinion on Drug Safety|May 5, 2025
Identification of drug combinations to reduce the risk of pioglitazone-related bladder cancer using the FDA adverse event reporting system databaseJun-Jie Yang, Hui Zhao, Ming-Ming Yan, et al.Expert Opinion on Drug Safety|April 30, 2025
Risk of thromboembolic events in patients co-treated with factor Xa-inhibiting direct oral anticoagulants and anti-seizure medications: insights from pharmacovigilance dataLingqing Ding, Congqin Chen, Yongkuan Yang, et al.Expert Opinion on Drug Safety|April 26, 2025
Nephrotoxicity risks of colistin-combination therapy: a USFDA adverse event reporting system analysis using disproportionality and interaction assessmentKannan SridharanExpert Opinion on Drug Safety|April 28, 2025
Two first-generation KRAS inhibitor safety profiles: a disproportionality analysis of individual reports from the FDA adverse event reporting systemYing Zhang, Shuhua Tong, Li WanExpert Opinion on Drug Safety|March 31, 2025
Adverse events associated with obeticholic acid: a real-world, pharmacovigilance studyChunxia Zhang, Jianguo WangExpert Opinion on Drug Safety|April 18, 2025
Attention to the interactions between vincristine and triazole antifungals: perspectives from real-world retrospective analysis and pharmacovigilance assessmentDan Huang, Ye Zhang, Lin Liu, et al.Expert Opinion on Drug Safety|April 23, 2025
The Impact of Medication Regimen Complexity Score on Multi-Organ Dysfunction and Clinical Outcomes in Critically Ill Patients: A Cohort StudyKholoud Al Aamer, Khalid Al Sulaiman, Ohoud Aljuhani, et al.Expert Opinion on Drug Safety|April 12, 2025
Comprehensive analysis of adverse drug reactions associated with teduglutide: post-marketing insights and safety implicationsPraneeth Kudaravalli, Michael B Andrews, Douglas G AdlerExpert Opinion on Drug Safety|April 12, 2025
Drug-induced Guillain-Barré Syndrome: a disproportionality analysis based on the US FDA adverse event reporting systemRujia Zhong, Jiahao Li, Feng Zhang, et al.Expert Opinion on Drug Safety|March 29, 2025
Infection toxicity assessment of tumor necrosis factor α inhibitors in the treatment of IBD: a real-world study based on the US food and drug administration adverse events reporting system (FAERS)Qian Cheng, Zeyu Yao, Xuan Shi, et al.Pageof 282